Speeches made during Parliamentary debates are recorded in Hansard. For ease of browsing we have grouped debates into individual, departmental and legislative categories.
These initiatives were driven by Baroness Ritchie of Downpatrick, and are more likely to reflect personal policy preferences.
A Bill to regulate and limit the practice of bottom trawling in marine protected areas; and for connected purposes.
Baroness Ritchie of Downpatrick has not co-sponsored any Bills in the current parliamentary sitting
The Government is committed to supporting the Northern Ireland Executive as appropriate in consulting with businesses, civil society groups, and representative organisations. There is regular contact between the Government and the Northern Ireland Executive on a range of issues and further detail will be provided in due course.
The Government understands that the availability of flexible working can be important for those who are pregnant and in work. It can be equally as important for a number of other groups, including new parents, those with other caring responsibilities and those managing a disability or long term health condition. That is why, through the Employment Rights Bill, the Government is making flexible working the default for all employees, except where not reasonably feasible.
The Employment Rights Bill establishes a new right to Bereavement Leave for employees to take protected time off to grieve. We will consult stakeholders on aspects of the design.
The Paternity Leave (Bereavement) Act 2024 enabled a ‘day one’ paternity leave entitlement for employees who become the primary carer for their newborn after the death of their partner. Regulations will then provide them with leave for up to one year after the child’s birth or adoption placement. This entitlement will have minimal impact on business and no impact on the Exchequer.
Acas maintain guidance for employers on bereavement including miscarriage.
The Employment Rights Bill establishes a new right to Bereavement Leave for employees to take protected time off to grieve. We will consult stakeholders on aspects of the design.
The Paternity Leave (Bereavement) Act 2024 enabled a ‘day one’ paternity leave entitlement for employees who become the primary carer for their newborn after the death of their partner. Regulations will then provide them with leave for up to one year after the child’s birth or adoption placement. This entitlement will have minimal impact on business and no impact on the Exchequer.
Acas maintain guidance for employers on bereavement including miscarriage.
The Employment Rights Bill establishes a new right to Bereavement Leave for employees to take protected time off to grieve. We will consult stakeholders on aspects of the design.
The Paternity Leave (Bereavement) Act 2024 enabled a ‘day one’ paternity leave entitlement for employees who become the primary carer for their newborn after the death of their partner. Regulations will then provide them with leave for up to one year after the child’s birth or adoption placement. This entitlement will have minimal impact on business and no impact on the Exchequer.
Acas maintain guidance for employers on bereavement including miscarriage.
The purpose of the UK’s arms export licensing criteria is to ensure that the Government’s decisions on export licences are informed by a set of criteria which promote global security and facilitate responsible exports. The Criteria enable the Government to operate one of the most robust and transparent export control regimes in the world. We consider all new licence applications against the Criteria and will refuse any which are inconsistent with them. Specifically, Criteria 2c states that the Government will not issue or maintain export licences if there is a clear risk that the items might be used to commit or facilitate serious violations of International Humanitarian Law.
The impact of ‘catfishing’ can be devastating for victims. Under the Online Safety Act all in-scope services will need to protect users from illegal content and criminal behaviour, including communications offences such as the false communications offence.
In addition, those services that are likely to be accessed by children will need to take steps to protect child users from content which is harmful. Ofcom will have robust powers enforce to against companies who do not comply with their duties
The impact of ‘catfishing’ can be devastating for victims. Under the Online Safety Act all in-scope services will need to protect users from illegal content and criminal behaviour, including communications offences such as the false communications offence.
In addition, those services that are likely to be accessed by children will need to take steps to protect child users from content which is harmful. Ofcom will have robust powers enforce to against companies who do not comply with their duties
The government consulted on the eligible entity criteria and procedural requirements for the super-complaints’ regime under the Online Safety Act 2023 earlier this year. We are carefully considering responses to the consultation to inform secondary legislation, which we intend to lay in spring next year.
The Online Safety Act requires all services in scope of the regime to proactively tackle and prevent users from being exposed to the most harmful illegal content, much of which disproportionately affects women and girls. Illegal content includes harassment, stalking, and controlling or coercive behaviour. Under the Act, services over the designated threshold will also need to remove certain types of legal content, such as content that is abusive on the basis of sex or gender, where it is prohibited in their terms of service. Companies will need to have effective, accessible mechanisms in place for users to be able to report abuse and receive an appropriate response from the platform.
The Online Safety Act gives online platforms new duties to protect users; this includes taking action against illegal content, such as harassment, and protecting children from harmful content. Ofcom is the regulator for this regime. It will have strong enforcement powers where providers fail to comply with their duties. It will be able to impose significant fines and, where appropriate, business disruption measures on non-compliant platforms. It can fine companies up to £18 million or 10% of their qualifying worldwide annual revenue.
The future of the Holiday Activities and Food programme beyond the 31 March 2025 is subject to the next government Spending Review taking place this autumn and the department will communicate the outcome of that process in due course.
I refer my noble Friend to the answer of 21 October 2024 to Question HL1266.
The future of the Holiday Activities and Food programme beyond 31 March 2025 is subject to the next government Spending Review taking place this autumn and the outcome of the review will be communicated in due course.
We recognise the need to take action to ensure that UK consumption of forest risk commodities is not driving deforestation, and we will set out our approach to addressing this in due course.
Defra continues to monitor and review the impacts of new controls introduced under the Border Target Operating Model (BTOM). We will work closely with industry, trade partners and enforcement agencies to minimise costs to trade and disruption, while continuing to protect our biosecurity.
The Government’s modelling of the inflationary impact of the BTOM uses a peer-reviewed econometric model, including the impacts of non-tariff measures related to checks such as the cost of Export Health Certificates and port fees, and upstream impacts such as administrative processing time, training, certificates of origin and security deposits or guarantees when moving agricultural goods under licence.
Analysis has indicated the BTOM policies would lead to an approximate increase in consumer food price inflation of less than 0.2 percentage points over a three-year period
An outbreak of a major disease could have a much more significant impact. The 2001 outbreak of Foot and Mouth disease cost £12.8 billion in 2022 prices, £4.8 billion of which was cost to Government and £8 billion cost to the private sector.
Following their meeting in Brussels on 2 October, the President of the European Commission and the Prime Minister have agreed to strengthen the relationship between the EU and UK, putting it on a more solid, stable footing. We have already said we will seek to negotiate a UK-EU veterinary/SPS agreement to help boost trade and deliver benefits to businesses and consumers in the UK and the EU. The UK and EU are like-minded partners with similarly high standards. We recognise that delivering new agreements will take time, but we are ambitious, have clear priorities and want to move forward at pace.
Food Security is national security which is relevant to all five Government Missions and central to our primary Mission to grow the economy. Boosting Britain’s food security is one of the core priorities of this Government.
We need a resilient and healthy food system that works with nature and supports British Farmers. We will do this by listening to farmers and others with a stake in our food system, countryside, and nature.
The Government recognises the valuable role Local Food Partnerships can play in this regard and welcomes their knowledge and expertise as we develop our plans to support our farmers and food and drink businesses, boost food security, and deliver growth.
The Government will explore how to build on existing place-based initiatives and how to create the best environment for sustainable growth, working in partnership with local leaders.
Not for EU’ labelling is a requirement of the Windsor Framework and does not represent a change in standards of production and quality. Defra works closely with the agri-food sector to support them with labelling requirements and to ensure the continued supply of goods into Northern Ireland. The previous Government consulted on the proposal to extend the 'Not for EU' labelling requirement across Great Britain. This Government is carefully considering the evidence provided and no legislation to give effect to these arrangements has yet been taken forward.
The BTOM sets outs out a risk-based, proportionate regime of controls which assesses the inherent biosecurity or public health risk presented by an import, together with the prevalence of relevant pests and diseases and our confidence in the exporting country’s production standards and health controls.
This assessment allows us to set controls at the most appropriate level and focus on the areas of highest risk to the UK. The goods posing the highest biosecurity risk are being prioritised as we build up to full check rates and high levels of compliance.
Defra in conjunction with the Department for Business and Trade will work to reset the relationship with our European friends to strengthen ties and tackle barriers to trade, while recognising that there will be no return to the single market or customs union.
We will tackle trade barriers through seeking to negotiate a veterinary / Sanitary and Phytosanitary agreement with the European Union to prevent unnecessary border checks and help tackle the cost of food.
I will update this House in due course on the next steps.
We recognise the importance of maintaining a thriving and competitive aviation sector in the UK that supports and strengthens Union connectivity.
Passengers between Belfast and London are well served with a choice of between 22 and 35 flights per day, depending on the season, between Belfast’s two airports (Belfast City and Belfast International) and five London airports (Gatwick, Heathrow, City, Luton and Stansted).
I recognise the importance of connectivity between London and Belfast and welcomed the recent Urgent Question on this issue earlier this month.
The Department meets regularly with airlines, including British Airways, to discuss a variety of topics. This includes operational performance and regional connectivity. The Department will continue to meet with airlines to discuss these topics going forward.
Government continues to work closely with the Kent and Medway Resilience Forum to ensure that well-rehearsed traffic management plans for freight and passenger traffic are in place ahead of the introduction of the European Union’s new Entry/Exit system (EES).
Driver welfare is an important factor during any disruption. KMRF has responsibility for providing welfare to freight and non-freight traffic during a period of significant congestion or gridlock on the road network in Kent. KMRF holds an established Driver Welfare Plan, this is currently being reviewed ahead of EES implementation.
The UK is working to deter and disrupt the Russian shadow fleet. At the European Political Community Summit in July, we led efforts to ask European partners to sign a Call for Action that seeks to address the risks that the shadow fleet poses to maritime safety and security, and, crucially, the environment.
The Department for Transport takes robust measures to ensure all sea vessels in UK territorial waters, including the Strait of Dover, comply with environmental law.
The government has implemented, and enforces, a variety of mandatory environmental measures related to the use and carriage of oil, including heavy fuel oil, by sea. International standards are primarily set out in the International Convention for the Prevention of Pollution from Ships (MARPOL), to which the UK is a signatory. Annex I of MARPOL makes provision for the prevention of pollution by oil from ships and includes mandatory requirements such as construction standards of oil tankers, limitations on size and arrangement of cargo tanks, damage stability requirements and a robust survey and certification regime. Compliance with these requirements is enforced by the Maritime and Coastguard Agency (MCA) through surveys of UK registered ships and Port State Control inspections of non-UK ships when in UK ports. Non-compliance is managed through the detention of ships, prohibition notices and, where necessary, prosecution.
With regard to insurance, within certain tonnage limitations, UK ships and ships coming to or from the UK must have certificates to prove that they have the relevant compulsory civil liability insurance against oil pollution and liability insurance for the locating, marking and removing of wrecks in the event that the ship causes a pollution incident or is wrecked. Insurers must meet the UK’s criteria to provide appropriate cover and be approved by the MCA before a compulsory insurance certificate can be issued.
The Department publishes Universal Credit statistics on Stat-Xplore which show there were 7.1 million people on Universal Credit in September 2024 and 5.6 million people on Universal Credit in September 2020.
The Department also publishes the benefit expenditure and caseload tables which reported an average caseload of 4.0 million people on Universal Credit in 2020-21.
There are a number of reasons for the increase in the caseload for Universal Credit. There is a maturing effect, as people on legacy benefits leave the system as their legacy claim ends, they appear as a new claim to Universal Credit. In addition, the Move to UC programme is driving up the caseload numbers as people are moved off legacy benefits onto Universal Credit as part of our migration programme.
Delivering our manifesto commitment to tackle child poverty is an urgent priority for this Government, and the Ministerial Taskforce is working to publish the Child Poverty Strategy in Spring 2025.
Our publication on 23 October ‘Tackling Child Poverty: Developing our Strategy’ sets out how we will develop the Strategy, harnessing all available levers to deliver a reduction in child poverty this Parliament.
The Strategy will look at policies across four key themes of increasing incomes, reducing essential costs, increasing financial resilience, and better local support especially in the early years. This will build on the reform plans underway across government and work underway in Devolved Governments.
The Taskforce will hear directly from experts on each of the Strategy’s themes. In October, they heard from partners in industry, regulation and the charity sector about options to reduce essential costs for low-income families. In November, employers, trade unions and think tanks will be invited to discuss options to increase incomes and financial resilience in low-income households.
The vital work of the Taskforce comes alongside our commitments to triple investment in breakfast clubs to over £30 million, introduce a Fair Repayment Rate for deductions from Universal Credit, and increase the National Living Wage to £12.21 an hour from April 2025 to boost the pay of 3 million workers.
£1 billion, including Barnett impact, will be invested to extend the Household Support Fund in England by a full year until 31 March 2026, on top of the six months already announced, and to maintain Discretionary Housing Payments in England and Wales. This will help struggling households facing the greatest financial hardship.
The latest statistics show that in 2022/23 there were 4.3 million children (30%) in relative low income after housing costs.
Statistics on the number of children living in absolute and relative poverty in the UK are published annually in the “Households Below Average Income” publication at Households below average income: for financial years ending 1995 to 2023 - GOV.UK (www.gov.uk)(opens in a new tab). The latest available data can also be found on Stat-Xplore: https://stat-xplore.dwp.gov.uk/. The latest statistics published on 21 March 2024 are for the financial period 2022/23.
Delivering our manifesto commitment to tackle child poverty is an urgent priority for this Government, and the Ministerial Taskforce is working to publish the Child Poverty Strategy in Spring 2025.
Our publication on 23 October ‘Tackling Child Poverty: Developing our Strategy’ sets out how we will develop the Strategy, harnessing all available levers to deliver a reduction in child poverty this Parliament.
The Strategy will look at policies across four key themes of increasing incomes, reducing essential costs, increasing financial resilience, and better local support especially in the early years. This will build on the reform plans underway across government and work underway in Devolved Governments.
The Strategy is building on a wealth of existing evidence and expertise from all relevant Departments, as is reflected in the broad membership of the Ministerial Taskforce. Ministers are also committed to leading discussions across all UK nations and regions.
The Taskforce will listen to experts and campaigners, engaging with charities, campaigners and leading organisations across the UK to shape and inform these plans, including hearing directly from families across the UK to gather insight.
While we cannot commit to changing the two child policy, tackling child poverty is at the heart of the Government’s mission to break down barriers to opportunity and improve the life chances of every child.
The Child Poverty Taskforce will explore how we can harness all available levers to reduce child poverty, including by listening to stakeholders on potential changes, before publishing a strategy in Spring 2025.
The lower rate of Universal Credit standard allowance for customers under 25 reflects the fact they are more likely to live in someone else’s household than customers 25 and over and are therefore likely to have lower living costs. They also typically earn less as they are earlier in their careers, with the lower rate maintaining the incentive to work.
The Government is committed to reviewing Universal Credit. Details of the review will be set out in due course.
£500 million is being provided to enable the current Household Support Fund, including funding for Devolved Administrations through the Barnett formula to be spent at their discretion. This means Local Authorities in England are receiving £421 million to support those in need locally.
The current Household Support Fund will be in place until 30 September 2024.
As a new government, we are reviewing all policies, including the Household Support Fund.
There have been five separate iterations of the Household Support Fund (HSF). Since the first iteration was introduced over £2.5 billion has been allocated to Local Authorities in England to distribute to those in need (October 2021- September 2024).
DWP requires that Local Authorities provide Management Information (MI) returns to the Department, which demonstrate that they are delivering the scheme in accordance with the guidance and grant determination that the Department have set out for the scheme. This includes information on the type of household supported, category of spending, types of support and how support has been accessed.
MI has been published for the first three iterations of HSF following their completion. The latest MI covering HSF3 was published in August 2023 and can be found here: Household Support Fund 3 management information for 1 October 2022 to 31 March 2023 - GOV.UK (www.gov.uk).
The MI shows that just under £1.3 billion was spent in England during HSF1-3, corresponding to 26 million individual awards. Approximately 66% of funding of HSF1-3 (around £800 million) was spent on households with children.
Additionally, DWP is conducting a process and impact evaluation of the fourth iteration of the Household Support Fund. This includes research with a selection of representative Local Authority case study areas, consisting of interviews with Local Authority officials and their delivery partners, and surveys and interviews with recipients of the HSF. This evaluation will provide key evidence on how Local Authorities are delivering the scheme and the impacts of the funding for recipients.
The Health Mission sets the objective of building a National Health Service fit for the future. As part of that work, and in response to Lord Darzi’s report, we have launched an extensive programme of engagement to develop a 10-Year Health Plan to reform the NHS. The plan will set out a bold agenda to deliver on the three big shifts, from hospitals to the community, from analogue to digital, and from sickness to prevention.
In addition, following publication of the 10-Year Health Plan, we will develop a new national cancer plan, which will include further details on how we will improve outcomes for cancer patients, including those with blood cancer.
We are now in discussions about what form that plan should take, and what its relationship to the 10-Year Health Plan and the Government’s wider Health Mission should be, and will provide updates on this, including on publication dates, at the earliest opportunity.
We are committed to tackling deaths from cardiovascular disease (CVD), of which there are far too many, and setting a goal for fewer lives being lost to the biggest killers, including CVD. The development of the Major Conditions Strategy was paused following the general election. NHS England’s 2019 Long Term Plan sets out a number of actions that aim to help prevent up to 150,000 heart attacks, strokes, and dementia cases by 2029, and progress towards this is ongoing. To deliver the National Health Service Long Term Plan priorities, a CVD programme has been established which is clinically led by national clinical directors and national specialty advisors, and supported by senior clinicians from a breadth of cardiac and stroke specialties, and primary care, as part of expert advisory groups.
Tackling waiting lists and ensuring that patients receive the care they need when they need it is a key part of our Health Mission. Funding announced in the Autumn Budget will support the delivery of an additional 2 million operations, scans, and appointments during our first year in Government, which is the equivalent to 40,000 per week, as a first step in our commitment to ensuring patients can expect to be treated within 18 weeks.
The NHS Health Check programme, England’s CVD prevention programme, finds people aged 40 to 74 years old who are at risk of CVD and supports them to reduce their risk, preventing approximately 500 heart attacks or strokes each year. To improve access and engagement with the life-saving programme, we are developing a digital NHS Health Check which will be ready for testing in early 2025, and will enable people to undertake a check at home. We are also trialling the delivery of heart health checks to over 130,000 people in workplaces across the country, all of which would improve earlier diagnosis of CVD.
At the 2024 Autumn Budget, my Rt Hon. Friend, the Chancellor of the Exchequer announced £1.5 billion of capital funding for new surgical hubs and diagnostic scanners. This will build capacity for over 30,000 additional procedures and over 1.25 million diagnostic tests, as well as new beds which will create more treatment space in emergency departments, reduce waiting times, and help shift more care into the community. We will also address the challenges in diagnostic waiting times, providing the number of computed tomography, magnetic resonance imaging, and other tests that are needed to reduce elective and cancer waits. Finally, the NHS is prioritising roll-out of additional diagnostic capacity, delivering the final year of the three-year investment plan for establishing Community Diagnostic Centres, with capacity prioritised for cancer diagnostics.
Heart valve disease (HVD) care in the United Kingdom has made strides in addressing treatment gaps, yet challenges such as late diagnosis, health disparities, and regional variations in care persist. NHS England is driving initiatives to improve pathways, reduce inequalities, and enhance access to timely and equitable care, while also addressing broader elective care pressures.
Significant progress is being made in the care and treatment of HVD patients in the UK. NHS England has established an expert advisory group to drive targeted pathway improvement projects, aiming to reduce referral-to-treatment times for severe valvular disease in 2024/25. Referral rates for cardiac rehabilitation have improved notably, rising from 7% in 2019 to 15% in 2024. Over 80% of heart failure patients consistently receive care from specialist teams, reflecting steady progress in specialist access.
Efforts to address health inequalities are also advancing, including a review of disparities in the presentation and treatment of conditions like aortic stenosis, and updates to primary care eLearning to improve early diagnosis. These strides demonstrate our commitment to improving outcomes in HVD care.
The Women's Health Strategy call for evidence in 2021 received nearly 100,000 responses from individuals, and over 400 written submissions from expert groups and researchers. It identified a range of issues with women’s healthcare, including women not feeling listened to by healthcare professionals, healthcare services not considering women’s needs by default, negative impacts of symptoms and conditions on women in the workplace, and under-representation of women in research.
When asked if a health condition or disability had impacted their experience in the workplace, three in five answered yes, the equivalent to 62%. The most common impact was increased stress levels, at 76%, but one in four also said that it had impacted their earnings, the equivalent to 26%, or opportunities for promotion, equivalent to 25%.
In 2023, the Department commissioned the London School of Hygiene and Tropical Medicine to undertake a Women’s Reproductive Health Survey. Findings indicate that one in 10 respondents, or 11.8%, missed, on average, three or more days of work or education due to heavy bleeding or pain during their period over the past year.
We are considering how to take forward the Women’s Health Strategy for England. The Government is committed to prioritising women’s health as we reform the National Health Service, and we will put women’s equality at the heart of our missions.
The Health Mission sets the objective of building a National Health Service fit for the future. As part of that work, and in response to the Darzi report, we have launched an extensive programme of engagement to develop a 10-Year Health Plan to reform the NHS. The plan will set out a bold agenda to deliver on the three big shifts from hospitals to the community, from analogue to digital, and from sickness to prevention.
In addition, following publication of the 10-Year Health Plan, we will develop a new national cancer plan, which will include further details on how we will improve outcomes for cancer patients.
We are now in discussions about what form that plan should take, and what its relationship to the 10-Year Health Plan and the Government’s wider Health Mission should be, and will provide updates on this, including on publication dates, at the earliest opportunity.
The National Framework for Children and Young People’s Continuing Care, published by the Department in January 2016, is intended to support good practice locally, providing guidance for integrated care boards (ICBs) and local authorities on the process for assessing, deciding, and agreeing packages of care for children and young people.
ICBs are responsible for the provision and commissioning of services to meet the needs of their local populations. NHS England plans to capture children and young people’s continuing care activity data as part of the All Age Continuing Care Patient Level Dataset, due for implementation from April 2025, and is committed to supporting ICBs to implement the National Framework for Children and Young People’s Continuing Care.
Department officials regularly discuss a range of issues with colleagues in NHS England and the National Institute for Health and Care Excellence (NICE), including access to new and innovative treatments for a range of diseases and conditions.
The NICE makes evidence-based recommendations for the National Health Service on whether new medicines should be routinely funded by the NHS, based on an assessment of their costs and benefits. The NICE is currently evaluating exagamglogene autotemcel within its licensed indication for treating sickle cell, and has not yet published final guidance.
The NICE will aim to publish guidance on any new, licensed treatment for sickle cell disease as soon as possible after licensing.
The Innovative Medicines Fund (IMF) was launched in June 2022 and builds on the successful Cancer Drugs Fund to support patient access to the most promising new medicines, while further evidence is collected on their use to address clinical uncertainty. £340 million is available through the fund this financial year for the National Health Service to fund early access to the most promising treatments, including gene therapies, while additional data is collected that will inform a future National Institute for Health and Care Excellence (NICE) evaluation to decide whether the medicine should be routinely funded. The NICE has recommended two treatments for use through the IMF, both of which are gene therapies, which are:
The National Institute for Health and Care Excellence (NICE) makes recommendations for the National Health Service on whether new medicines should be routinely funded by the NHS, based on an assessment of their costs and benefits. The NHS in England is legally required to fund NICE-recommended medicines, normally within three months of the publication of final guidance. The NICE only recommends medicines that offer additional health benefits to patients and their carers, and demonstrate value for money for the taxpayer.
The NICE is currently evaluating two new licensed disease-modifying treatments for Alzheimer’s disease and has been unable to recommend them in its draft guidance. The NICE concluded that the relatively small benefits they provide balanced against the overall cost of providing the treatments, including intensive monitoring for serious side effects, means that they cannot currently be considered good value for the taxpayer. However, the NICE has not yet published final guidance and will take the comments received in response to its draft guidance fully into account in developing its final recommendations.
A number of other disease-modifying treatments for dementia are in late-stage development and are expected to come to market in the next few years. To prepare for the new generation of dementia treatments in development, NHS England is working to ensure that diagnostic and treatment capacity, and clinical pathway redesign and investment are in place to support the adoption of any new licensed and NICE recommended treatments as soon as possible.
The Government will transform the NHS from a late diagnosis, late treatment health service, to one that catches illness earlier and prevents it in the first place. We will also put Britain at the forefront of transforming treatment for dementia by backing more research into the disease. Part of this will be ensuring that we support manufacturers to develop products that are potentially cost effective to implement, and that new treatments assessed as clinically and cost effective are rolled out in a safe and timely way.
The Department funds dementia research via the National Institute for Health and Care Research (NIHR). Alongside Alzheimer’s Research UK, Alzheimer’s Society, and the People’s Postcode Lottery, the NIHR is funding the Blood Biomarker Challenge which seeks to produce the clinical and economic data that could make the case for the use of a blood test in the NHS to support diagnosis of dementia.
The National Institute for Health and Care Excellence (NICE) makes recommendations for the National Health Service on whether new medicines should be routinely funded by the NHS, based on an assessment of their costs and benefits. The NHS in England is legally required to fund NICE-recommended medicines, normally within three months of the publication of final guidance. The NICE only recommends medicines that offer additional health benefits to patients and their carers, and demonstrate value for money for the taxpayer.
The NICE is currently evaluating two new licensed disease-modifying treatments for Alzheimer’s disease and has been unable to recommend them in its draft guidance. The NICE concluded that the relatively small benefits they provide balanced against the overall cost of providing the treatments, including intensive monitoring for serious side effects, means that they cannot currently be considered good value for the taxpayer. However, the NICE has not yet published final guidance and will take the comments received in response to its draft guidance fully into account in developing its final recommendations.
A number of other disease-modifying treatments for dementia are in late-stage development and are expected to come to market in the next few years. To prepare for the new generation of dementia treatments in development, NHS England is working to ensure that diagnostic and treatment capacity, and clinical pathway redesign and investment are in place to support the adoption of any new licensed and NICE recommended treatments as soon as possible.
The Government will transform the NHS from a late diagnosis, late treatment health service, to one that catches illness earlier and prevents it in the first place. We will also put Britain at the forefront of transforming treatment for dementia by backing more research into the disease. Part of this will be ensuring that we support manufacturers to develop products that are potentially cost effective to implement, and that new treatments assessed as clinically and cost effective are rolled out in a safe and timely way.
The Department funds dementia research via the National Institute for Health and Care Research (NIHR). Alongside Alzheimer’s Research UK, Alzheimer’s Society, and the People’s Postcode Lottery, the NIHR is funding the Blood Biomarker Challenge which seeks to produce the clinical and economic data that could make the case for the use of a blood test in the NHS to support diagnosis of dementia.
The apheresis working group was established to address issues around apheresis capacity and improve the resilience of stem cell supply for the United Kingdom. The working group is currently in the evidence gathering phase ahead of publishing its report in spring 2025.
The group is comprised of stakeholders from apheresis users, commissioning bodies, patient representatives, and subject matter experts. Each member has a responsibility for keeping wider stakeholders informed. The Cell and Gene Therapy Catapult is already represented within the working group. The catapult is responsible for coordination of the Advanced Therapy Treatment Centre network. Through submissions from, and engagement with, the Cell and Gene Therapy Catapult, a report is in preparation on apheresis capacity across users to be discussed at the next working group meeting.